All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the Acute Leukemia Forum 2021, the AML Hub spoke to James Foran, Mayo Clinic, Jacksonville, US. We asked, In what patients would you replace 7+3 with venetoclax-based therapies?
In what patients would you replace 7+3 with venetoclax-based therapies?
Historically, older patients with AML have been undertreated due to the barriers involved in treatment with intensive chemotherapy. In this video, Foran discusses the usage of venetoclax-based therapies with a focus on this patient subset. He believes that longer follow-up and prospective data are needed in order to offer the azacitidine/venetoclax combination to more patients.
Emerging immunotherapy modalities in AML and exciting data from ASH 2019
Naval Daver talks about emerging immunotherapies in the field of AML. He describes the expansion of knowledge in this field and how that has helped improve patient outcomes,...
Hot off the ASCO press: leukemia and transplant highlights
At the 2019 ASCO Annual Meeting in Chicago, US, steering committee member, Gail Roboz from Weill Cornell Medicine, New York, US, shares highlights from the leukemia and transplant session.
Subscribe to get the best content related to AML delivered to your inbox